
Curis, Inc. (NASDAQ:CRIS – Free Report) – Analysts at HC Wainwright raised their FY2026 earnings per share estimates for shares of Curis in a research note issued on Friday, November 13th. HC Wainwright analyst S. Nik now anticipates that the biotechnology company will earn ($8.05) per share for the year, up from their previous estimate of ($15.65). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Curis’ current full-year earnings is ($15.65) per share. HC Wainwright also issued estimates for Curis’ Q4 2026 earnings at ($0.51) EPS and FY2027 earnings at ($0.65) EPS.
Curis (NASDAQ:CRIS – Get Free Report) last released its earnings results on Thursday, November 12th. The biotechnology company reported ($1.94) EPS for the quarter, beating analysts’ consensus estimates of ($2.01) by $0.07.
Other equities analysts have also issued research reports about the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a research report on Thursday, October 15th. Wall Street Zen raised shares of Curis from a “strong sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Finally, Zacks Research raised shares of Curis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, September 9th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Curis has an average rating of “Hold” and an average target price of $43.00.
Check Out Our Latest Analysis on CRIS
Curis Stock Down 2.1%
Shares of CRIS stock opened at $0.44 on Tuesday. The business’s fifty day moving average is $0.75 and its 200 day moving average is $8.12. The stock has a market cap of $1.79 million, a price-to-earnings ratio of -0.07 and a beta of 3.28. Curis has a twelve month low of $0.33 and a twelve month high of $28.40.
Institutional Trading of Curis
A number of hedge funds have recently made changes to their positions in the stock. Focused Wealth Management Inc purchased a new stake in shares of Curis in the 2nd quarter worth approximately $26,000. BlackRock Inc. bought a new position in Curis during the 2nd quarter valued at approximately $28,000. Flputnam Investment Management Co. purchased a new position in Curis during the second quarter valued at $128,000. Renaissance Technologies LLC raised its stake in Curis by 52.2% during the first quarter. Renaissance Technologies LLC now owns 366,740 shares of the biotechnology company’s stock valued at $201,000 after buying an additional 125,823 shares during the last quarter. Finally, Cable Car Capital LP purchased a new position in Curis during the second quarter valued at $696,000. 29.97% of the stock is owned by institutional investors.
About Curis
Curis, Inc. is a clinical-stage biotechnology company focused on developing treatments for cancer. Its research centers on targeted therapies designed to interfere with biological pathways involved in tumor growth and survival. The company’s clinical pipeline has included emavusertib, an oral small-molecule inhibitor of IRAK4 and FLT3 being investigated for certain blood cancers and other malignancies. Curis has also worked with partners to develop cancer drug candidates. Historically, Curis collaborated with Genentech on the development of Erivedge (vismodegib), a Hedgehog pathway inhibitor approved to treat certain cases of advanced basal cell carcinoma.
Read More
- Five stocks we like better than Curis
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.
